CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2023		406,387
Beginning balance at Dec. 31, 2023	$ 661,021	$ 4,064	$ 1,986,899	$ (1,326,826)	$ (2,298)	$ (818)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(6,034)			(6,064)		30
Other comprehensive income (loss)	(449)				(449)
Exercise of stock options (in shares)		1,434
Exercise of stock options	2,455	$ 14	2,441
Vesting of restricted stock units (in shares)		1,170
Vesting of restricted stock units	0	$ 11	(11)
Shares withheld related to net share settlement (in shares)		(122)
Shares withheld related to net share settlement	(646)	$ (1)	(645)
Issuance of common stock (in shares)		1,974
Issuance of common stock	15,230	$ 20	15,210
Stock-based compensation expense	16,909		16,909
Ending balance, (in shares) at Mar. 31, 2024		410,843
Ending balance at Mar. 31, 2024	$ 688,486	$ 4,108	2,020,803	(1,332,890)	(2,747)	$ (788)
Beginning balance (in shares) at Dec. 31, 2024	412,194	412,194
Beginning balance at Dec. 31, 2024	$ 470,952	$ 4,122	2,053,895	(1,586,977)	(88)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	12,112			12,112
Other comprehensive income (loss)	631				631
Vesting of restricted stock units (in shares)		871
Vesting of restricted stock units	0	$ 8	(8)
Shares withheld related to net share settlement (in shares)		(42)
Shares withheld related to net share settlement	(161)		(161)
Stock-based compensation expense	$ 16,720		16,720
Ending balance, (in shares) at Mar. 31, 2025	413,023	413,023
Ending balance at Mar. 31, 2025	$ 500,254	$ 4,130	$ 2,070,446	$ (1,574,865)	$ 543